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Summary
Neuroblastoma is a pediatric malignancy that typically arises in early childhood and is derived 
from the developing sympathetic nervous system. Clinical phenotypes range from localized 
tumors with excellent outcomes to widely metastatic disease where long-term survival is 
approximately 40% despite intensive therapy1. A previous genome-wide association study 
(GWAS) identified common polymorphisms at the LMO1 gene locus that are highly associated 
with neuroblastoma susceptibility and oncogenic addiction to LMO1 in the tumor cells2. Here we 
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sought to discover the causal DNA variant at this locus and the mechanism by which it leads to 
neuroblastoma tumorigenesis. We first imputed all possible genotypes across the LMO1 locus and 
then mapped highly associated single nucleotide polymorphism (SNPs) to areas of chromatin 
accessibility, evolutionary conservation, and transcription factor binding sites. SNP rs2168101 
G>T was the most highly associated variant (combined P=7.47×10-29, Odds Ratio 0.65, 95% CI: 
0.60-0.70) and resided in a super-enhancer defined by extensive acetylation of histone H3 lysine 
27 within the first intron of LMO1. The ancestral G-allele that is associated with tumor formation 
resides in a conserved GATA transcription factor binding motif. We show that the newly evolved 
protective TATA allele is associated with decreased total LMO1 expression (P=0.028) in 
neuroblastoma primary tumors and ablates GATA3 binding (P<0.0001). We demonstrate allelic 
imbalance favoring the G-containing strand in tumors heterozygous for this SNP as demonstrated 
both by RNA sequencing (P<0.0001) and reporter assays (P=0.002). These findings show that a 
recently evolved polymorphism within a super-enhancer element in the first intron of LMO1 
influences neuroblastoma susceptibility through differential GATA transcription factor binding 
and direct modulation of LMO1 expression in cis, and this leads to an oncogenic dependency in 
tumor cells.
GWAS efforts frequently identify highly statistically significant genetic associations within 
non-coding regulatory regions of the genome3, but the underlying causal DNA sequence 
variations have only been identified in a few instances4-6. A neuroblastoma GWAS has 
identified multiple disease susceptibility loci2,7-13, with the signal within the LIM domain 
only 1 (LMO1) locus at 11p152, a transcriptional co-regulator containing two zinc finger 
LIM domains that nucleate and regulate transcription factor complexes14, being most robust. 
The main members of the LMO gene family, LMO1-4, are all implicated in cancer including 
LMO1 and LMO2 translocations in T-cell leukemia15,16, and we previously provided the 
first evidence that LMO1 was a bona fide neuroblastoma oncogene2. Here, we sought to 
identify the causal polymorphism(s) driving the LMO1 genetic association with 
neuroblastoma susceptibility as a basis for understanding neuroblastoma initiation and 
addiction mechanisms.
We first performed fine mapping of associated germline SNPs and indels at the LMO1 gene 
locus by imputation to the 1000 Genomes Project for our European-American 
neuroblastoma GWAS11. This identified 27 SNPs with minor allele frequency (MAF) >0.01 
and an association P<1×10-5 (Figure 1A, Extended Data Table 1). We further prioritized 
associated variants by evolutionary conservation, and by their regulatory potential inferred 
through neuroblastoma-specific DNase I hypersensitivity mapping and chromatin 
immunoprecipitation sequencing (ChIP-Seq) from the ENCODE Consortium (Figure 1B). 
These data showed that the most significantly associated SNP at the LMO1 locus 
(rs2168101, OR=0.67, P=4.14×10-16) resides within a highly conserved and active enhancer 
region inferred by DNase I sensitivity and p300 binding in the SKNSH neuroblastoma cell 
line (Figure 1B). Importantly, we found no rare or common non-synonymous coding 
variants in LMO1 in a combined cohort of 482 unique neuroblastoma cases with germline 
whole-genome (N=136), whole-exome (N=222), and/or targeted DNA sequencing (N=183) 
(see Extended Data Table 2 and Supplemental Data).
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Because rs2168101 genotypes were imputed in our analyses (Extended Data Figure 1), we 
next directly genotyped this SNP in 146 of 2101 European-American cases, and measured 
an 86% imputation accuracy (Supplemental Table 1). We additionally directly genotyped 
rs2168101 in two independent cohorts from the United Kingdom and Italy, with both 
showing robust replication (Table 1). We did not observe replication in an independent 
African-American cohort17. Notably, the protective T-allele is common in Europeans (CEU 
HapMap: 28%) and East Asians (CHB+JPT HapMap: 32%), but is rare or absent in 
Africans, indicating recent expansion of the rs2168101 protective allele in non-African 
human populations. Meta-analysis demonstrated a combined association P=7.47×10-29 
across 8553 controls and 3254 cases (Table 1).
As causal SNPs driving GWAS associations may disrupt transcription factor binding at 
distal enhancers6,18,19, we sought to identify candidate SNPs disrupting known JASPAR 
motifs20, which revealed that lead candidate SNP rs2168101 resides in a highly conserved 
GATA-binding motif (5′-A[G/T]ATAA-3′, mammalian phastCons score=100%) (Figure 
1B). ENCODE transcription factor ChIP-Seq confirmed GATA2 and GATA3 binding at the 
rs2168101 GATA motif in the neuroblastoma cell lines SKNSH and SHSY5Y, which are 
G/G homozygous, thereby preserving the GATA motif (Figure 1B). No other associated 
variant showed this unique combination of evolutionary conservation, active enhancer 
localization, and disruption of a transcription factor binding motif, including the sentinel 
SNP rs110419 (P=1.17×10-13) from our original report.2
In order to test for the possibility of multiple statistical signals or enhancers not marked by 
conservation or p300 at the LMO1 locus, we repeated association testing conditional on 
imputed rs2168101 genotypes and observed no significant variants after multiple test 
correction (most significant variant: rs34544683, nominal P=9.0×10-4, Bonferroni P=1; 
Extended Data Figure 2A). To test if the rs2168101 signal can be equally captured by other 
variants, we also performed reciprocal association tests for rs2168101 conditioned upon all 
27 other SNPs within 1.5 Mb of LMO1 passing thresholds MAF>0.01 and nominal 
P<1×10-5. Notably, rs2168101 remained significant across all conditional tests (worst-case 
nominal P=2.6×10-7, Bonferroni P=0.002; Extended Data Figure 2B). These results are 
consistent with a single underlying signal at the LMO1 locus, and re-affirm that rs2168101 is 
the single best causal SNP candidate, because its association with neuroblastoma cannot be 
accounted for by other variants.
We next sought to determine if rs2168101 genotypes were associated with LMO1 expression 
by mRNA-sequencing of 127 primary high-risk neuroblastoma tumors. Genotyping 
rs2168101 yielded 102 G/G, 25 G/T, and no T/T tumors (MAF=9.8%). We observed 
significantly higher LMO1 expression in G/G versus G/T genotype tumors (T-test P=0.028; 
Figure 2A). Notably, the absence of protective homozygous T/T genotypes in this high-risk 
neuroblastoma cohort is consistent with our prior observation that the risk alleles predispose 
to the high-risk phenotypic subset2 (for clinical covariate associations, see Extended Data 
Table 3). Accordingly, the rs2168101 G/G genotype is highly associated with decreased 
neuroblastoma patient event-free (P=0.0004) and overall (P=0.0004) survival compared to 
G/T and T/T genotypes together in our European-American cohort (Extended Data Figure 
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3). Two cell lines with homozygous T/T or T/- genotypes expressed LMO1 at comparatively 
lower levels than cell lines containing the G-allele (Extended Data Figure 4A).
GATA transcription factors mediate chromatin looping and facilitate long-range enhancer-
promoter interactions to regulate target gene expression21. We therefore sought to confirm 
allelic imbalance of LMO1 transcripts (a hallmark of gene regulation in cis), which could 
result from differential GATA-binding caused by rs2168101. First, because the rs2168101 
intronic SNP is not detectable by mRNA sequencing, we identified the LMO1 exonic 
synonymous SNP, rs3750952, which can measure allelic expression in the heterozygous 
state. We identified 45 tumors with the necessary rs3750952=C/G genotype, and then 
directly genotyped rs2168101 (G/G=33, G/T=12, T/T=0) in this panel. By mRNA-Seq, there 
was greater allelic imbalance in 12 tumors that were heterozygous for rs2168101 (G/T) 
compared to 33 homozygous tumors (rs2168101=G/G; T-test P<0.0001; Figure 2B). We 
next used targeted sequencing of nuclear-enriched nascent RNAs in four neuroblastoma cell 
lines (G/G=1, G/T=2, T/T=1) to provide direct ascertainment of allele-specific expression at 
rs2168101. In both heterozygous lines, we observed allelic imbalance that significantly 
favored the risk G-allele over the protective T-allele (Figure 2C). Collectively, these results 
indicate that the intact GATA motif at rs2168101 results in significantly higher LMO1 
expression levels than the TATA coded by the alternative allele. Allelic imbalance of LMO1 
was not driven by somatic DNA alterations (e.g. loss of heterozygosity) that could affect 
allelic dosage (Extended Data Figure 4B).
Examination of neuroblastoma transcriptome data for 127 primary tumors showed that 
GATA2 and GATA3 are overexpressed compared to other members of the GATA 
transcription factor family (Extended Data Figure 5A) and that GATA3 is the most highly 
expressed. Additionally, protein immunoblotting showed that GATA3 is uniformly highly 
expressed in neuroblastoma cell lines, while LMO1 is highly expressed in the G/G (SKNSH 
and SHSY5Y), G/- (KELLY) and G/T (IMR32) cell lines, but only barely detectable in the 
BE2C cell line that lacks a G-allele at the rs2168101 locus (Extended Data Figure 5B). We 
therefore performed ChIP-Seq using a GATA3 antibody in neuroblastoma cell lines and 
observed robust GATA3 binding at rs2168101 in lines containing the G-allele (SHSY5Y, 
KELLY, BE2, and NGP) but not in a line containing only a T-allele (BE2C) (Figure 3A). 
We then specifically considered GATA3 ChIP-seq reads overlapping rs2168101, and we 
observed strong preferential binding to the G-allele in the G/T heterozygous cell lines BE2 
(0.97 G-allele fraction from 38 reads, 95% CI: [0.86, 1.00], Binomial test P=2.8×10-10) and 
NGP (1.00 G-allele fraction from 6 reads, 95% CI: [0.54, 1.00], Binomial test P=0.03) 
(Figure 3B).
Acetylation of histone H3 at lysine 27 (H3K27ac) is a hallmark of active enhancers22, and 
ChIP-seq analysis of SHSY5Y (G/G; not MYCN amplified), KELLY (G/-; MYCN 
amplified), BE2 (G/T; MYCN amplified), and NGP (G/T; MYCN amplified) neuroblastoma 
cells showed extensive H3K27 acetylation in the first intron of LMO1 across rs2168101, that 
was not observed in BE2C (T/-; MYCN amplified; Figure 3C). This region is classified as a 
super-enhancer in G-allele containing lines SHSY5Y, KELLY, and BE2 based on enhancer 
clustering and especially high H3K27ac signal (NGP was just below the threshold; see 
Methods), a pattern also observed for other known oncogenes and tumor suppressor genes in 
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this disease (Figure 3D, Extended Data Figure 6A)23. No super-enhancer was observed in 
BE2C, Jurkat T-ALL cells that also express LMO124, or in other non-neuroblastoma tissues 
from ENCODE (Figure 3D, Extended Data Figure 6B-C). These results are consistent with 
recent evidence that disease-associated SNPs frequently affect enhancers that are specific to 
disease-relevant cell lines and tumor histology, and control developmental stage and tissue-
specific gene expression5,23,25-28.
We next performed luciferase reporter assays to measure the effect of rs2168101 alleles on 
enhancer activity. HEK293T cells transfected with constructs containing the risk G-allele 
demonstrated 30-300 fold higher normalized luminescence compared to the T-allele (T-test 
P=0.002, Figure 3E), whereas luciferase activity of the T-allele was not significantly 
different from empty vector, indicating that the intact GATA motif is required for robust 
enhancer activity. Finally, knockdown of GATA3 in SHSY5Y and KELLY cells resulted in 
both decreased LMO1 protein levels and suppression of cell growth that was rescued by 
LMO1 overexpression (Figure 3F, Extended Data Figure 7), indicating the central role of 
GATA3 in regulating LMO1 expression levels in neuroblastoma.
Taken together, these data demonstrate the underlying molecular mechanism for a highly 
robust genetic association to neuroblastoma, mediated by a single common causal SNP 
rs2168101 that disrupts a GATA transcription factor binding site within a tissue-specific 
super-enhancer element. The rarity or absence of the protective allele in African populations 
and its relative depletion in African-Americans may partially explain the more aggressive 
clinical course in African-American children29. Moreover, this work further confirms the 
utility of association studies to define clinically relevant oncogenic pathways. Finally, the 
dependence of neuroblastoma cells on super-enhancer-mediated LMO1 expression provides 
another potential mechanism for the sensitivity of these tumors to inhibitors of the 
transcriptional machinery such as CDK7 and BET bromodomain proteins25,27, 
demonstrating the potential of translating basic mechanistic insights of tumor initiation 
towards novel therapeutic strategies.
Online methods
Genotype imputation and association testing
A primary European-American cohort of 2101 cases and 4202 matched controls were 
assayed with Illumina HumanHap550 v1, Illumina HumanHap550 v3, and Illumina 
Human610 SNP arrays as previously described11. Genotypes were phased using SHAPEIT 
v2.r790 and data from 1000 Genomes phase 1 version 3. Subsequently, imputation was 
performed using IMPUTE2 v2.3.1 for all SNPs and indel variants annotated in the 1000 
Genomes phase 1 version 3. Testing for association with neuroblastoma under an additive 
genetic effect model was performed using the frequentist likelihood score method 
implemented in SNPTEST v2.4.1. Genotypes for a previously described African-American 
cohort of 365 cases 2491 controls17 were imputed and tested for neuroblastoma association 
using the same analytic pipeline. Statistical adjustment for gender was performed in both 
cohorts. For population stratification adjustment, the first 20 multidimensional scaling 
(MDS) components were included as covariates in the European-American cohort, while a 
measure of African admixture as estimated by the ADMIXTURE software program was 
Oldridge et al. Page 5
Nature. Author manuscript; available in PMC 2016 March 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
used in the African-American cohort. Manhattan plots of SNP position and statistical 
significance were generated using LocusZoom software. Linkage plots were generated by 
Haploview software based on HapMap CEU individuals (Version 3, Release 2) using default 
settings. All research subjects or their guardians provided informed consent for research, and 
all institutions involved in this research had regulatory approval for human subjects 
research.
Prioritization of candidate causal variants
All SNPs and indels reported in the 1000 Genomes phase 1 version 3 data were considered 
as candidate causal variants and were ranked based on a combination of 1) neuroblastoma 
association in the primary European-American cohort, 2) evolutionary conservation, 3) 
DNase I hypersensitivity, and 4) transcription factor binding motif matching. Neuroblastoma 
association in European-Americans was evaluated as described above. Conservation scores 
were computed as the average of the phastCons46wayPlacental UCSC conservation track 
score for all bases from the -10 position to the +10 position surrounding each candidate 
variant. A DNase I hypersensitivity score was calculated by counting the number of 
sequencing tags from the -100 position to the +100 position around each candidate variant in 
ENCODE data for the neuroblastoma cell line, SK-N-SH. Position weight matrices 
representing transcription factor binding motifs were obtained from the JASPAR database, 
and candidate binding sites were identified by scanning the hg19 human reference genome 
using the MATCH-TM algorithm with a matrix similarity score (mSS) threshold of 0.90.
Neuroblastoma association replication and meta-analysis for rs2168101
We replicated the association of rs2168101 with neuroblastoma by direct genotyping of 
rs2168101 in independent Italian (Cases=420, Controls=751) and United Kingdom cohorts 
(Cases=369, Controls=1109). Meta-analysis across the European-American, African-
American, Italian, and United Kingdom cohorts was performed using the inverse variance 
method provided in the METAL software program. Beta values (log-odds) and standard 
errors generated by SNPTEST, as described above, were used as input.
Survival analysis
We compared both overall survival and event-free survival over a 10-year follow-up period 
between G/G vs. G/T and T/T rs2168101 genotypes in a case-case comparison between 
neuroblastoma patients from the European-American cohort. Because rs2168101 genotypes 
were imputed in this cohort, the most-probable genotype predicted by IMPUTE2 was used 
for each patient. In the event of insufficient follow-up, all data was right censored. Cox 
proportional hazard modeling was performed using 20 MDS components to account for 
population stratification, in addition to MYCN amplification status, as covariates. All 
statistical analysis and generation of Kaplan-Meier plots was performed in R using the 
CRAN repository package, ‘survival’.
Total and allele-specific expression analysis
Total and allele-specific RNA expression analysis was performed based on poly-A enriched 
RNA-sequencing data from 127 primary neuroblastoma tumors sequenced through the 
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TARGET project. RNA-seq reads were aligned to the hg19 human reference genome using 
the STAR aligner (v2.4.0b). Aligned reads were assigned to RefSeq genes using HTSeq 
(v0.6.1) and normalized to reads per kilobase per million reads (RPKM) for total gene 
expression measurements. DNA genotypes for rs2168101 were obtained either through 
matched whole-genome sequencing (N=69) or targeted genotyping assays (N=58 additional 
tumors). DNA genotypes for rs3750952 were obtained either through matched whole-
genome or whole-exome sequencing.
Allele-specific RNA expression analysis was performed from a subset of 45 primary 
neuroblastoma tumors (out of 127) with the necessary synonymous exonic SNP genotypes 
(rs3750952=C/G) to enable measurement of allelic expression by mRNA-Seq. As a readout 
for allelic imbalance of rs3750952, we computed allelic fractions as min(C, G) / (C + G), 
since phasing between rs3750952 and rs2168101 alleles in each tumor was unknown. 
Statistical comparison between the two groups was performed by two-sided Welch's T-test, 
comparing 12 tumors heterozygous for rs2168101 (G/T) to the remaining 33 tumors that 
were homozygous for rs2168101 (G/G) as controls. DNA genotyping for rs2168101 was 
performed by whole-genome sequencing or a directed genotyping assay, whereas DNA 
genotyping for rs3750952 was determined from TARGET whole-exome or whole-genome 
sequencing. Where possible, integrity of sample matching was verified by measurement of 
genome-wide genotype concordance. All genotypes are reported with respect to the minus 
strand of the human reference genome, hg19.
To measure allele-specific expression directly at the intronic SNP we first purified the 
nuclear RNA fraction using the Cytoplasmic and Nuclear RNA purification Kit, (Norgen 
Biotek, Cat.#21000, Ontario, Canada) from four neuroblastoma cell lines (SNP rs2168101: 
SHSY5Y=G/G; NLF=G/T; NGP=G/G; NB1643=T/T). Ion AmpliSeq Designer v3.4.3 (Life 
Technologies White Glove service, Austin, USA) was used to design amplicons targeting 
the intronic SNP rs2168101 and three additional exonic SNPs in linkage disequilibrium. 
Custom AmpliSeq libraries were prepared in triplicate for each cell line, indexed, pooled 
and sequenced using an Ion 318 Chip on a Personal Genome Machine (Life Technologies). 
Reads were aligned to the hg19 reference genome and a synthetic genome showing the 
alternate allele at SNP rs2168101 at hg19 chr11:8255408 to account for any alignment bias. 
High quality mapped reads containing the reference G-allele or alternate T-allele were 
counted and tested for significant deviation from 50:50 expression using a two-sided one-
sample T-test (null hypothesis that allele fraction = 0.50) across three experimental 
replicates. Primers pair sequences:
F: GTGTGGGAGACAAAUTCTTCCUGA R: GCCGGGCGUTACTGAACUT
F: CGCAAGAUCAAGGACCGCTAUC R: GATGAGGTUGGCCTTGGTGUA
F: CCUTTCCUGAAGGAGCGCAAA R: CACTTTCCATUAAGGAGATAGCAUCCC
F: CAAUCTAGGTUAAGAGCCGGACAAG R: GTGUCCAGCCGCAGCUA
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Reporter Assays
Primers were designed to clone a 553bp genomic region (hg19, chr11:8255155-8255707) 
surrounding the candidate SNP rs2168101 at the GATA transcription factor binding site 
from neuroblastoma cell lines SKNSH (G/G) and matching site of BE2C (T/-). The cloned 
region did not contain other statistically significant SNPs at the LMO1 locus. The primers 
were designed to introduce sequences for restriction sites 5′-XhoI and 3′-BglII, which are 
present in the MCS of pGL4.26[luc2/minP/Hygro] (Promega Cat# E8441). XhoI/BglII 
restriction enzyme digested fragments were sequence verified, gel purified, ligated into 
pGL4.26[luc2/minP/Hygro], transformed into One Shot TOP 10 chemically competent cells 
(Life Technologies Cat # C4040-10) and grown on LB plates containing 50ug/ml ampicillin 
overnight at 37C. Colonies positive for the vector containing the insert were grown in 50 ml 
LB broth containing 50ug/ml ampicillin and plasmids were purified using a Qiagen Plasmid 
Midi Prep Kit (Qiagen Cat# 12143). Transfection into HEK293 cells which were 
approximately 50% confluent was accomplished using Fugene 6 Transfection reagent 
(Promega E2691) at a 3 ul:1ug fugene:DNA ratio. Cells underwent selection in 150ug/ml 
Hygromycin B (Mediatech, Inc. Cat#30-240-CR) and individual colonies were picked and 
grown, and genotypes of constructs were confirmed by fragment size and Sanger 
sequencing. Subsequently, HEK293 + 553bp insert cells and HEK294 + vector only cells 
were grown in 96 well optical plates. On day 2, the cells were transiently fugene transfected 
with the Renilla expression control vector pGL4.74[hRLuc/TK] (Promega Cat# E6921) at a 
1:500 dilution with respect to the luciferase vector. Luciferase assays were carried out 48 
hours after Renilla transfection using Dual Luciferase Reporter Assay System (Promega 
E1910) with read-outs performed on a Dual Injector System for GloMax®-Multi Detection 
System (Promega Cat# E7081). Luciferase expression was normalized to Renilla expression. 
All reporter assays were performed in quintuplicate (five technical replicates each) across 
the experimental conditions: 1) HEK293T, 2) HEK293T with empty vector, 3-6) four 
independent clones of HEK293T with T-allele construct, and 7-10) four independent clones 
of HEK293T with G-allele construct. Results were averaged across technical replicates, 
normalized to empty vector, and reporter activities for T-allele vs. G-allele clones (four 
biological replicates each) were analyzed by two-sided Welch's T-test.
Construct risk allele (G)—
GTAGGGGTTGGAGTTCAGCCTGTTTCCCCTCCAATGTTGTTCCCCCCACATCCTG
AGACTTAGGGGTGACCCTGGGTTGAGTGGACTGGTTTATTCTGCTGGGCCCAGC
GCATGCATCTGAGTGTGTGCCCAGGCGTGCGTGTCGGCGCAAACATCATCCATT
GTGAAATATCAGTGTTTTCATGGGTGAGTAGTAATTACTGGGTAATGCTTTAAA
ACCTTTCCTGAAGGAGCGCAAAGCCATTTTTTTCTAAAGTCAGGAGTACATTAA
AAGGATTACCATGTAGATTTGATTTTTAGAT
AACACTAAAATGGATCCCAAATGGACTTCAGCAAAGGGATGCTATCTCCTTAATGGAAAGTGCATGGCCCGAGGCTCAGGTCCCAGAGCCAGGCTGGGGAAGGAGGGAGGGAAGAGGTGTCTGCAGGGGGGCAGGCTGGCAGATTGGGTGGGGGCTAGGTGGGAATGGGGAAGGCAGAGCAGGAGGGAGGGCCTGGACCCTGTGGGGAGCTTATCCCTCCATCTGGGGAGCAGGAGACTACAGAGCCCCT
Construct protective allele (T)—
GTAGGGGTTGGAGTTCAGCCTGTTTCCCCTCCAATGTTGTTCCCCCCACATCCTG
AGACTTAGGGGTGACCCTGGGTTGAGTGGACTGGTTTATTCTGCTGGGCCCAGC
GCATGCATCTGAGTGTGTGCCCAGGCGTGCGTGTCGGCGCAAACATCATCCATT
GTGAAATATCAGTGTTTTCATGGGTGAGTAGTAATTACTGGGTAATGCTTTAAA
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ACCTTTCCTGAAGGAGCGCAAAGCCATTTTTTTCTAAAGTCAGGAGTACATTAA
AAGGATTACCATGTAGATTTGATTTTTATAT
AACACTAAAATGGATCCCAAATGGACTTCAGCAAAGGGATGCTATCTCCTTAATGGAAAGTGCATGGCCCGAGGCTCAGGTCCCAGAGCCAGGCTGGGGAAGGAGGGAGGGAAGAGGTGTCTGCAGGGGGGCAGGCTGGCAGATTGGGTGGGGGGCTAGGTGGGAATGGGGAAGGCAGAGCAGGAGGGAGGGCCTGGACCCTGTGGGGAGCTTATCCCTCCATCTGGGGAGCAGGAGACTACAGAGCCCCT
Cell Culture and Protein Lysates
Jurkat T-ALL and neuroblastoma cell lines were sourced from the American Type Tissue 
Culture Collection, and kept in growth medium of RPMI+10% heat-inactivated FCS with 
1% penicillin-streptomycin, as previously described24. Cells were lysed for protein, with 
subsequent protein quantified by spectrophotometry, as previously described (Mansour et al, 
2014). Protein was resolved on 8-14% Tris-Bis gels, transferred to PVDF membranes, 
blocked and subjected to primary and secondary antibodies, as previously described 
(Mansour et al, 2014). Primary antibodies were anti-GATA3 (Pierce Biotechnology, 
1:1000), anti-LMO1 (Bethyl Laboratories, 1:1000) and alpha-tubulin (Cell Signaling 
Technologies, 1:1000). Blots were developed with secondary HRP-conjugated antibodies 
(Cell Signaling Technologies, 1:5000) and Protein-plus Dura ECL Reagent (Thermo-Fisher 
Scientific). All cell lines are genotyped semiannually to assure identity and also tested 
routinely for mycoplasma contamination.
Genome-wide occupancy analysis
ChIP coupled with massively parallel DNA sequencing (ChIP-seq) was performed as 
previously described31,32. The following antibodies were used for ChIP: anti-H3K27ac 
(Abam, ab4729) and anti GATA3(Santa Cruz, sc-22206X). For each ChIP, 10 μg of 
antibody was added to 3 ml of sonicated nuclear extract. Illumina sequencing, library 
construction and ChIP-seq analysis methods were previously described32. ChIP-seq datasets 
are available under super series GSE65664, and relevant accession numbers are shown in 
Supplemental Table 2.
ChIP-Seq processing
Reads were aligned to build hg19 of the human genome using bowtie with parameters –k 2 –
m 2 –e 70 –best and –l set to the read length33. For visualization in the UCSC genome 
browser in Figure 3A, 3C, and Extended Data Figure 634, WIG files were created from 
aligned ChIP-Seq read positions using MACS 1.4.2 with parameters –w –S –space=50 –
nomodel –shiftsize=200 to artificially extend reads to be 200bp and to calculate their density 
in 50bp bins35. Read counts in 50bp bins were then normalized to the millions of mapped 
reads, giving reads per million (rpm) values.
ChIP-Seq allele specificity analysis
To determine preferential ChIP-Seq coverage of one allele, which implies preferential 
binding of protein to one allele vs. another, we counted the reads at rs2168101 using 
samtools mpileup36. By using the aligned reads described above, this gave us a count of 
reads with a given base at this position. The fraction of reads with the risk allele vs. the 
protective allele is reported in Figure 3B. Statistical tests for preferential allelic binding were 
performed by two-sided binomial test.
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Enriched regions
Regions enriched in ChIP-Seq signal were identified twice using MACS with corresponding 
control and parameters –keep-dup=all and –p 1e-9 or –keep-dup=1 and –p 1e-9. Super-
enhancers in SHSY5Y and KELLY were identified using ROSE (https://bitbucket.org/
young_computation/rose)28,37 with modifications inspired by Chipumoro et al.25. Briefly, 
peaks of H3K27ac were identified using MACS as described above and their union was 
used as constituent enhancers. These peaks were stitched computationally if they were 
within 12500bp of each other, though peaks fully contained within +/-2000bp from a RefSeq 
promoter were excluded from stitching. These stitched enhancers were ranked by their 
H3K27ac signal (length * density) with input signal in the corresponding region subtracted. 
Super-enhancers were separated from typical enhancers by geometrically determining the 
point at which the line y=x is tangent to the curve of stitched enhancer rank vs. stitched 
enhancer signal. Those stitched enhancers above this point are considered super-enhancers.
To account for the known focal amplification of the MYCN locus in KELLY, BE2, BE2C, 
and NGP neuroblastoma cells, which contain enhancers, we modified our pipeline slightly. 
Because MACS is insensitive for the identification of peaks in focally amplified DNA, we 
identified peaks of H3K27ac vs. input using MACS2 callpeak (https://pypi.python.org/pypi/
MACS2) with parameters –broad –keep-dup=1 –p 1e-9 and –broad –keep-dup=all –p 1e-9. 
The union of these MACS2 calls was used as constituent enhancers for ROSE with the 
remaining parameters as described above. For Figure 3D, the majority of the curve 
represents the analysis performed using MACS-identified constituents; the rank and signal 
of the MYCN-associated enhancer comes from this MACS2-identified set of constituents to 
remain consistent with the conclusions and methods as previously described25. The curve 
output from the MACS-identified enhancers was vertically compressed and a point 
representing the signal of the MYCN-associated super-enhancer from the MACS2-identified 
enhancers was added in Illustrator. Super-enhancers were assigned to the single expressed 
RefSeq transcript whose TSS was nearest the center of the stitched region. Expressed genes 
were in the top 2/3 of RefSeq transcripts ranked by their promoter (TSS +/- 500bp) 
H3K27ac signal determined by bamToGFF (https://github.com/BradnerLab/pipeline) with 
parameters –e 200 –m 1 –r –d.
Clone Cell Generation
LMO1 cDNA was amplified from pcDNA3-LMO1 and subcloned into the XhoI and NotI 
site of the lentiviral vector pOZ-FHN. Lentivirus expressing FH-LMO1 was propagated in 
HEK293T cells by cotransfection with psPAX2 and pMD2.G plasmids (adgene) using 
FUGENE 6 (Roche) by standard methodologies38. Viral supernatant was recovered and 
KELLY cells were infected with lentivirus expressing FH-LMO1 or empty vector alone, as 
previously described24. Cells were sorted for expression of the IL2R, and positive 
expression was used to establish single cell clones. Expression of FH-LMO1 was assessed 
by western blotting as above to confirm overexpression.
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siRNA and growth assays
SHSY5Y, KELLY, and KELLY clone cells were reverse transfected with 100 nM 
concentrations of either non-targeted (Control siRNA #1) or GATA3-targetted siRNA #1 or 
#2 (Ambion) for 6h with lipofectamine 2000 (1:1000) in Optimem I prior to being replated 
into growth assays in normal RPMI growth media. 2×105 cells were replated in triplicate for 
counting at 24, 48 and 72h post-transfection by manual hemocytometry. 5×105 cells were 
replated for protein lysates at the same time points. All experiments were repeated in 
triplicate, with a technical replicate number of 9 for all cell growth assays as described39. 
Statistical tests were performed by two-sided Welch's T-test.
Data Access
GWAS and sequencing data used for this analysis are available in dbGaP under accession 
phs000124 and phs000467. The tumor genomics data are also available through the 
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) data 
matrix portal (http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html). Data 
generated through the ENCODE project including DNase I hypersensitivity sequencing and 
ChIP-sequencing data were obtained from ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/
encodeDCC/. Aligned sequencing read (bam) files were utilized as provided from the FTP 
site. The mammalian evolutionary conservation track representing 46 mammalian species 
(phastCons46wayPlacental) was obtained from the UCSC Table Browser http://
genome.ucsc.edu/cgi-bin/hgTables?command=start. JASPAR-annotated transcription factor 
binding site position frequency matrices were obtained from http://jaspar.genereg.net/html/
DOWNLOAD/JASPAR_CORE/pfms/pfms_all.txt. New ChIP-seq datasets generated in this 
study are available under super series GSE65664.
Extended Data
Extended Data Figure 1. 
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Extended Data Figure 2. 
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Extended Data Figure 3. 
Extended Data Figure 4. 
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Extended Data Figure 5. 
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Extended Data Figure 6. 
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Extended Data Figure 7. 
Extended Data Table 1
Variant ID (rsID) Chromosome Position (hg19) Alleles (Ref/Alt)*
Alt Allele 
Frequency 
Cases
Alt Allele 
Frequency 
Controls
P-Value† Odds Ratio†
rs191871553 11 8222464 C/T 0.035 (n=2101) 0.054 (n=4202) 7.49E-06 0.64 (0.53-0.78)
rs11041809 11 8231605 A/G 0.498 (n=2101) 0.440 (n=4202) 1.13E-07 0.80 (0.74-0.87)
rs11041811 11 8231665 C/T 0.492 (n=2101) 0.434 (n=4202) 1.28E-07 0.80 (0.74-0.87)
rs11041812 11 8231684 C/T 0.492 (n=2101) 0.433 (n=4202) 1.22E-07 0.80 (0.74-0.87)
rs11041813 11 8235207 T/C 0.478 (n=2101) 0.420 (n=4202) 1.67E-07 0.81 (0.75-0.87)
rs10839999 11 8236083 G/A 0.480 (n=2101) 0.423 (n=4202) 5.06E-07 0.81 (0.75-0.88)
rs10769885 11 8236262 C/A 0.513 (n=2101) 0.453 (n=4202) 3.77E-08 0.80 (0.74-0.87)
rs4758049 11 8238428 A/C 0.511 (n=2101) 0.452 (n=4202) 7.48E-08 0.81 (0.74-0.87)
rs4758050 11 8238545 G/C 0.511 (n=2101) 0.452 (n=4202) 7.34E-08 0.81 (0.74-0.87)
rs4758051 11 8238639 G/A 0.510 (n=2101) 0.452 (n=4202) 1.22E-07 0.81 (0.75-0.87)
rs10840000 11 8240113 G/C 0.509 (n=2101) 0.450 (n=4202) 6.22E-08 0.80 (0.74-0.87)
rs7933766 11 8240464 G/A 0.511 (n=2101) 0.453 (n=4202) 2.09E-07 0.81 (0.75-0.88)
rs11041816 11 8243798 A/G 0.397 (n=2101) 0.456 (n=4202) 8.99E-10 0.77(0.71-0.84)
rs4315061 11 8247020 T/C 0.425 (n=2101) 0.490 (n=4202) 1.25E-09 0.78 (0.72-0.84)
rs72474792 11 8247885 TATAAAA/T 0.524 (n=2101) 0.456 (n=4202) 2.04E-10 0.77(0.71-0.84)
rs12797723 11 8247984 C/T 0.443 (n=2101) 0.514 (n=4202) 2.05E-10 0.77(0.71-0.84)
rs2290451 11 8248440 C/G 0.295 (n=2101) 0.255 (n=4202) 8.20E-06 1.23(1.12-1.34)
rs7952320 11 8250143 G/C 0.408 (n=2101) 0.480 (n=4202) 3.03E-11 1.31 (1.21-1.42)
rs4758317 11 8250811 C/A 0.514 (n=2101) 0.447 (n=4202) 5.76E-10 0.78 (0.72-0.84)
rs11041820 11 8251438 G/A 0.294 (n=2101) 0.253 (n=4202) 6.77E-06 1.23 (1.12-1.34)
rs3750952 11 8251921 G/C 0.408 (n=2101) 0.481 (n=4202) 1.89E-11 0.76 (0.70-0.83)
rs110419 11 8252853 A/G 0.441 (n=2101) 0.511 (n=4202) 3.16E-10 0.78 (0.72-0.84)
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Variant ID (rsID) Chromosome Position (hg19) Alleles (Ref/Alt)*
Alt Allele 
Frequency 
Cases
Alt Allele 
Frequency 
Controls
P-Value† Odds Ratio†
rs 110420 11 8253049 T/C 0.441 (n=2101) 0.511 (n=4202) 3.36E-10 0.78 (0.72-0.84)
rs204928 11 8254433 A/G 0.444 (n=2101) 0.512 (n=4202) 9.85E-10 0.78 (0.72-0.85)
rs204926 11 8255106 G/A 0.440 (n=2101) 0.510 (n=4202) 1.97E-11 0.76 (0.70-0.82)
rs2168101 11 8255408 C/A 0.242 (n=2101) 0.313 (n=4202) 4.14E-16 0.67(0.61-0.74)
rs7948497 11 8255855 C/G 0.479 (n=2101) 0.419 (n=4202) 4.05E-10 1.30(1.20-1.41)
Extended Data Table 2
Characteristic
Whole Exome 
Sequencing (Blood 
and Tumor) 
N=222*
Whole Genome 
Sequencing (Blood 
and Tumor) N = 
136*
LMO1 Targeted 
Sequencing (Blood) 
N = 183*
Whole Transcriptome 
mRNA Sequencing 
(Tumor) N = 127
Age
 < 18 mos 0 (0%) 32 (24%) 82 (45%) 8 (6%)
 >= 18 mos 219 (100%) 103 (76%) 101 (55%) 119 (94%)
 Not Available 3 1 0 0
INSS Stage†
 Stage 1 0 (0%) 0 (0%) 39 (21%) 0 (0%)
 Stage 2A 0 (0%) 0 (0%) 13 (7%) 0 (0%)
 Stage 2B 0 (0%) 1 (1%) 18 (10%) 0 (0%)
 Stage 3 0 (0%) 6 (4%) 27 (15%) 6 (5%)
 Stage 4 219 (100%) 105 (78%) 78 (43%) 121 (95%)
 Stage 4S 0 (0%) 23 (17%) 8 (4%) 0 (0%)
 Not Available 3 1 0 0
MYCN
 Not Amplified 143 (67%) 102 (76%) 151 (83%) 95 (75%)
 Amplified 71 (33%) 32 (24%) 30 (17%) 31 (25%)
 Not Available 8 2 2 1
Histology
 Favorable 4 (2%) 29 (23%) 95 (54%) 9 (8%)
 Unfavorable 187 (98%) 96 (77%) 82 (46%) 107 (92%)
 Not Available 31 11 6 11
DNA Index
 Hyperdiploid 117 (54%) 81 (61%) 121 (67%) 67 (53%)
 Diploid 98 (46%) 52 (39%) 59 (33%) 59 (47%)
 Not Available 7 3 3 1
Risk
 Low 0 (0%) 15 (11%) 64 (35%) 0 (0%)
 Intermediate 0 (0%) 14 (10%) 49 (27%) 6 (5%)
 High 219 (100%) 106 (79%) 69 (38%) 121 (95%)
 Not Available 3 1 1 0
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Extended Data Table 3
Clinical/Biological Co-variate
rs2168101 genotypes* Association result
GG GT TT P-Value† Odds Ratio†
Stage‡ 4 530 (62%) 280 (33%) 49 (6%) 0.01198 0.81 (0.69-0.95)
Not Stage 4 611 (56%) 400 (37%) 74 (7%)
MYCN Amplified 183 (55%) 115 (34%) 36 (11%) 0.00297 1.39 (1.12-1.73)
MYCN Non-Amplified 881 (59%) 525 (35%) 83 (6%)
High-Risk 523 (63%) 263 (32%) 47 (6%) 0.00174 0.76 (0.65-0.90)
Not High-Risk 594 (56%) 398 (37%) 73 (7%)
Unfavorable Histology 454(61%) 237 (32%) 48 (6%) 0.14479 0.88 (0.73-1.05)
Favorable Histology 527 (57%) 336 (36%) 62 (7%)
DNA Index Hyperdiploid 685 (59%) 412(35%) 71 (6%) 0.32009 0.91 (0.76-1.09)
DNA Index Diploid 324 (57%) 198(35%) 43 (8%)
Age >= 18 mos 621 (61%) 346 (34%) 55 (5%) 0.01448 0.82 (0.69-0.96)
Age < 18 mos 529 (57%) 338 (36%) 68 (7%)
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Imputation-based GWAS and epigenomic profiling by ENCODE identifies rs2168101 
as a candidate functional SNP at LMO1
(A) Manhattan plot for neuroblastoma GWAS. The neuroblastoma-associated region falls 
within a 40kb haplotype block (gray box) in Europeans, encompassing the LMO1 3′-
terminus. rs2168101 is the most associated variant and is moderately correlated (maximum 
r2=0.52) with other variants. The sentinel SNP reported previously, rs110419, is also 
highlighted#. (B) Associated variants (P<1×10-5) are plotted with ENCODE tracks for 
neuroblastoma cell line SKNSH. Two SNPs, rs2168101 and rs7948497, were annotated as 
“enhancer SNPs” based on overlapping DNase peaks binding p300. The rs2168101 G>T 
SNP disrupts the G-site of an evolutionarily conserved GATA transcription factor motif (5′-
A[G/T]ATAA-3′). SKNSH has a rs2168101=G/G genotype that preserves GATA binding, 
supported by ENCODE GATA3 ChIP-seq.
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Figure 2. RNA expression of LMO1 associates with rs2168101 genotype consistent with 
regulation in cis
(A) mRNA-Seq across 127 primary tumors genotyped for rs2168101 (G/G=102, G/T=25, 
T=0) revealed a significant decrease in LMO1 gene expression between G/T vs. G/G tumors 
(T-test P=0.028). (B) Using the synonymous exonic SNP, rs3750952, to measure allelic 
expression by mRNA-seq revealed significantly more allelic imbalance in 12 heterozygous 
neuroblastoma tumors (rs2168101=G/T) versus 33 homozygous tumors (rs2168101=G/G) 
(T-test P=5.3×10-5). (C) Allelic expression for rs2168101 from targeted nascent RNA-seq in 
four neuroblastoma cell lines. The two heterozygous cell lines (rs2168101=G/T) exhibited 
significantly reduced T-allele expression compared to the G-allele across 3 duplicate 
experiments (T-test P=1.6×10-4 and 1.5×10-2 for NGP and NLF, respectively; error bars 
denote 95% CIs).
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Figure 3. The rs2168101 protective T-allele disrupts GATA3-binding and negatively associates 
with the LMO1 super-enhancer in neuroblastoma cells
(A) Normalized GATA3 ChIP-seq signal at rs2168101 in five neuroblastoma cell lines 
(rs2168101 genotypes: SHSY5Y=G/G, KELLY=G/-, BE2=G/T, NGP=G/T, BE2C=T/-). (B) 
Allele-specific binding of GATA3 at rs2168101. GATA3 binding highly favored the risk G-
allele in heterozygous lines (BE2: 0.97 G-allele fraction from 38 reads, 95% CI: [0.86, 
1.00], Binomial P=2.8×10-10; NGP: 1.00 G-allele fraction from 6 reads, 95% CI: [0.54, 
1.00], Binomial P=0.03). (C) Normalized ChIP-seq signal for H3K27ac at rs2168101. (D) 
Ranked H3K27ac signal across all enhancers in MYCN-amplified KELLY and BE2C lines. 
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Super-enhancers associate with key neuroblastoma genes, highlighted on the curve. There is 
an LMO1-associated super-enhancer in G-allele-containing lines SHSY5Y, KELLY, and 
BE2, but not in BE2C, which lacks the G-allele. (E) Luciferase reporter assay for LMO1 
enhancer region. The risk G-allele preserved enhancer activity (T-test P=0.002 across four 
independent clones), whereas the protective T-allele was indistinguishable from empty 
vector. (F) Left: Protein blots for GATA3, LMO1, and tubulin in SHSY5Y cells treated with 
control or siRNAs targeting GATA3, at 72hrs post-treatment. Right: Cell counts for lines 
SHSY5Y, KELLY, KELLY stably overexpressing control vector (EV) and KELLY with 
forced LMO1 overexpression (LMO1-1 and LMO1-2) treated with siRNAs at 72h post-
transfection (see Extended Data Figure 7 for complete growth curves). Rescue of suppressed 
cell growth after GATA3 depletion by forced LMO1 expression was observed at 72h. Error 
bars denote +/- S.E.M. *P<0.05, ** P<0.001 by T-test.
Oldridge et al. Page 24
Nature. Author manuscript; available in PMC 2016 March 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Oldridge et al. Page 25
Ta
bl
e 
1
R
ep
lic
at
io
n 
an
d 
m
et
a-
an
al
ys
is 
of
 r
s2
16
81
01
 a
ss
oc
ia
tio
n
SN
P
R
ef
/A
lt 
(M
ajo
r/M
ino
r) 
Al
lel
e
C
oh
or
t
M
A
F 
C
as
es
M
A
F 
C
on
tr
ol
s
A
dd
iti
ve
 P
-v
al
ue
A
dd
iti
ve
 O
dd
s R
at
io
H
et
 O
dd
s R
at
io
 
(G
T 
vs
. G
G)
H
om
 O
dd
s R
at
io
 
(T
T 
vs
. G
G)
rs
21
68
10
1
G
/T
Eu
ro
pe
an
 A
m
er
ic
an
*
0.
24
2 
(n=
21
01
)
0.
31
3 
(n=
42
02
)
4.
14
E-
16
0.
67
 (0
.61
-0.
74
)
0.
69
 (0
.62
-0.
77
)
0.
52
 (0
.42
-0.
64
)
Ita
lia
n
0.
16
4 
(n=
42
0)
0.
25
0 
(n=
75
1)
2.
07
E-
06
0.
61
 (0
.50
-0.
75
)
0.
57
 (0
.44
-0.
74
)
0.
40
 (0
.21
-0.
75
)
U
ni
te
d 
K
in
gd
om
0.
19
0 
(n=
36
9)
0.
31
1 
(n=
11
09
)
5.
86
E-
10
0.
56
 (0
.47
-0.
68
)
0.
51
 (0
.39
-0.
66
)
0.
31
 (0
.18
-0.
53
)
A
fri
ca
n 
A
m
er
ic
an
*
0.
08
65
 (n
=3
64
)
0.
08
91
 (n
=2
49
1)
0.
20
0.
79
 (0
.56
-1.
13
)
0.
96
 (0
.71
-1.
30
)
1.
07
 (0
.38
-3.
04
)
Co
m
bi
ne
d
7.
47
E-
29
0.
65
 (0
.60
-0.
70
)
0.
67
 (0
.61
-0.
73
)
0.
49
 (0
.41
-0.
59
)
*
=
 im
pu
te
d 
ge
no
ty
pe
s a
nd
 c
or
re
ct
io
n 
fo
r p
op
ul
at
io
n 
str
at
ifi
ca
tio
n
Nature. Author manuscript; available in PMC 2016 March 02.
